On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.

Despite the company announcing on August 12 that its core product Ivonescimab (PD-1/VEGF bispecific antibody) received NMPA approval for its third indication — first-line treatment of advanced squamous non-small cell lung cancer in combination with chemotherapy — the stock failed to sustain gains and retreated amid broader sector weakness. The approval was based on positive results from the Phase III HARMONi-6 study comparing Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.

The biotech sector was broadly under pressure on the day, with ZAI LAB down 4.51%, BEONE MEDICINES down 1.64%, REMEGEN down 1.33%, SKB BIO down 0.48%, and INNOVENT BIO down 0.42%. AKESO's decline exceeded the sector average, suggesting profit-taking pressure following the prior catalyst being priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)